4//SEC Filing
AILERON THERAPEUTICS INC 4
Accession 0000899243-17-017894
$RNTXCIK 0001420565operating
Filed
Jul 4, 8:00 PM ET
Accepted
Jul 5, 8:25 PM ET
Size
19.3 KB
Accession
0000899243-17-017894
Insider Transaction Report
Form 4
Kapnick Scott
Director
Transactions
- Purchase
Common Stock
2017-07-05$15.00/sh+66,666$999,990→ 521,049 total(indirect: See Footnote) - Conversion
Series D-1 Preferred Stock
2017-07-05−363,636→ 0 total→ Common Stock (36,594 underlying) - Conversion
Series E-2 Preferred Stock
2017-07-05−612,002→ 0 total→ Common Stock (61,588 underlying) - Conversion
Series F Preferred Stock
2017-07-05−487,776→ 0 total→ Common Stock (49,086 underlying) - Conversion
Series D Preferred Stock
2017-07-05−106,856→ 0 total→ Common Stock (10,753 underlying) - Purchase
Common Stock
2017-07-05$15.00/sh+159,307$2,389,605→ 454,383 total - Conversion
Common Stock
2017-07-05+285,438→ 295,076 total - Conversion
Series E-3 Preferred Stock
2017-07-05−1,266,130→ 0 total→ Common Stock (127,415 underlying)
Footnotes (2)
- [F1]The Series D, Series D-1, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series D-1, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]These shares are directly owned by Jake86 LLC, for which the Reporting Person serves as investment manager. The Reporting Person disclaims beneficial ownership of the shares held by Jake86 LLC, except to the extent of his indirect pecuniary interest therein.
Documents
Issuer
AILERON THERAPEUTICS INC
CIK 0001420565
Entity typeoperating
Related Parties
1- filerCIK 0001420565
Filing Metadata
- Form type
- 4
- Filed
- Jul 4, 8:00 PM ET
- Accepted
- Jul 5, 8:25 PM ET
- Size
- 19.3 KB